Last updated: July 31, 2026
Tauvid, or flortaucipir F 18 injection, is an FDA-approved positron emission tomography (PET) diagnostic for estimating the density and distribution of aggregated tau neurofibrillary tangles in the brains of adults being evaluated for Alzheimer’s disease. It is marketed by Avid Radiopharmaceuticals, a subsidiary of Eli Lilly and Company. Tauvid is an imaging agent, not a treatment, and its commercial value depends on PET capacity, specialist adoption, reimbursement, and the growth of anti-amyloid treatment pathways.
Tauvid received FDA approval on May 28, 2020, under NDA 212123. The FDA label limits its use to estimation of tau pathology and states that a positive scan does not independently establish the diagnosis of Alzheimer’s disease. Tauvid has no biosimilar exposure, while conventional generic competition is limited by its radioactive formulation, specialized manufacturing, short effective shelf life, and PET distribution requirements.[1]
What is Tauvid and how does it work?
Tauvid contains flortaucipir F 18, a fluorine-18-labeled small molecule that crosses the blood-brain barrier and binds to aggregated tau protein deposits associated with Alzheimer’s disease. The fluorine-18 isotope has a physical half-life of approximately 110 minutes, requiring regional production and rapid administration.
Tauvid is administered intravenously before PET imaging. The approved adult dose is 370 MBq, with an allowable range of 111 to 370 MBq. Imaging generally begins approximately 80 minutes after injection.[1]
What does Tauvid diagnose?
Tauvid is indicated for estimating the density and distribution of aggregated tau neurofibrillary tangles in adults with cognitive impairment who are being evaluated for Alzheimer’s disease.
The product does not:
- Treat Alzheimer’s disease.
- Confirm Alzheimer’s disease without clinical correlation.
- Determine whether a patient will respond to an Alzheimer’s treatment.
- Replace clinical examination, cognitive testing, MRI, or other diagnostic assessments.
- Provide an approved measure of treatment response.
The FDA label warns that image interpretation can be difficult because of nonspecific uptake, off-target binding, and reader variability. Interpretation must be performed by readers trained in Tauvid PET image analysis.[1]
What clinical trials supported Tauvid approval?
Tauvid approval relied on clinical studies assessing the relationship between flortaucipir PET findings, neuropathology, and reader performance.
| Development element |
Evidence base |
| Active ingredient |
Flortaucipir F 18 |
| FDA application |
NDA 212123 |
| Approval date |
May 28, 2020 |
| Sponsor and marketer |
Avid Radiopharmaceuticals, Eli Lilly |
| Primary imaging use |
Estimation of aggregated tau neurofibrillary tangles |
| Population |
Adults with cognitive impairment evaluated for Alzheimer’s disease |
| Imaging modality |
Brain PET |
| Key validation standard |
Neuropathologic assessment and expert image interpretation |
| Regulatory category |
Diagnostic radiopharmaceutical |
The pivotal evidence showed that Tauvid PET could identify patterns associated with tau pathology, but performance varied by disease stage and region. The FDA required labeling that emphasizes trained interpretation and clinical correlation rather than use as an independent diagnostic test.[1]
What are the main clinical limitations?
Tauvid has several limitations that affect both clinical uptake and commercial use:
- Tau binding is not perfectly specific to Alzheimer’s disease pathology.
- Early or low-level tau deposition can be difficult to classify.
- Image interpretation requires reader training.
- Tauvid does not establish the presence of amyloid pathology.
- The test does not measure neuronal injury directly.
- PET infrastructure is concentrated in major hospitals and imaging centers.
The practical role of Tauvid is strongest when clinicians need additional information about disease staging, atypical presentations, or the likelihood that cognitive impairment is related to Alzheimer’s pathology.
What clinical trials are studying Tauvid after approval?
Post-approval flortaucipir research has focused primarily on observational imaging, disease progression, clinical-trial enrichment, and comparisons with other tau PET tracers. Most studies have not been designed to establish Tauvid as a therapeutic product.
Main post-approval research categories
| Research category |
Commercial relevance |
| Longitudinal tau accumulation |
Supports disease-progression measurement |
| Alzheimer’s staging |
Helps classify patients by tau burden |
| Anti-amyloid treatment studies |
May provide downstream disease characterization |
| Comparative tau-PET studies |
Tests performance against newer tracers |
| Imaging standardization |
Determines whether results are reproducible across sites |
| Clinical-trial enrichment |
Helps recruit patients with biomarker-confirmed disease |
| Neuropathology correlation |
Strengthens diagnostic validity |
ClinicalTrials.gov records have included observational studies using flortaucipir F 18 to evaluate tau deposition in Alzheimer’s disease and related neurodegenerative conditions. These studies have generally been sponsored by academic medical centers, imaging networks, pharmaceutical companies, or public research organizations.[2]
Tauvid’s role may expand in trials of disease-modifying therapies. Anti-amyloid drugs such as lecanemab and donanemab have increased the importance of biomarker-defined patient selection. Tau PET can help identify patients with more advanced neurofibrillary pathology, although amyloid PET or cerebrospinal-fluid and blood biomarkers are usually more directly relevant to confirming amyloid eligibility.
How does Tauvid compare with other tau PET tracers?
Tauvid was the first FDA-approved tau PET imaging agent, giving it regulatory precedence and early clinical adoption. Its competitive position is challenged by newer tracers with different binding profiles, imaging characteristics, or development strategies.
| Product or tracer |
Sponsor or developer |
Regulatory position |
Primary competitive issue |
| Tauvid, flortaucipir F 18 |
Avid, Eli Lilly |
FDA-approved |
Established label and commercial infrastructure |
| MK-6240 |
Merck and academic collaborators |
Investigational |
Strong research use and high-affinity tau imaging |
| RO6958948, also called PI-2620 |
Roche and academic developers |
Investigational or research use depending on jurisdiction |
Potentially improved selectivity and broader development interest |
| [18F]MK-6240 and related tracers |
Multiple research groups |
Investigational |
Competition in clinical trials and biomarker research |
| Amyloid PET agents |
Multiple sponsors |
Several FDA-approved products |
Different biological target and more direct anti-amyloid eligibility role |
Tauvid’s principal advantage is approval and commercial availability. Its principal risk is that sponsors may select newer tracers for clinical trials if those agents provide better off-target performance, regional quantification, or compatibility with global trial operations.
What is the FDA regulatory status of Tauvid?
Tauvid is FDA-approved under NDA 212123. It is a diagnostic radiopharmaceutical, not a biologic and not a small-molecule therapeutic in the conventional treatment sense.
FDA status summary
| Regulatory item |
Status |
| FDA approval |
Approved |
| Approval date |
May 28, 2020 |
| NDA |
212123 |
| Indication |
Estimation of aggregated tau neurofibrillary tangles |
| Pediatric approval |
Not established as a routine use |
| Treatment claim |
None |
| Companion-diagnostic designation |
Not approved as a formal companion diagnostic for a specific therapy |
| Distribution model |
Specialized radiopharmaceutical supply chain |
Tauvid does not have the exclusivity profile of a conventional therapeutic drug. Its protection depends more heavily on regulatory exclusivity, intellectual property, manufacturing know-how, site accreditation, reader training, and distribution capacity.
What patents protect Tauvid?
Publicly available regulatory materials identify Tauvid as flortaucipir F 18 injection marketed by Avid Radiopharmaceuticals. The commercially important intellectual-property assets are expected to include composition, radiolabeling, imaging-use, formulation, and manufacturing rights developed through Avid and related academic work.
A definitive commercial analysis must distinguish between:
- Patents covering the flortaucipir chemical entity.
- Patents covering fluorine-18 radiolabeling methods.
- Patents covering imaging methods for tau pathology.
- Patents licensed from universities or research institutions.
- Patents that may be listed in the FDA Orange Book.
- Unpublished manufacturing know-how and production specifications.
Tauvid’s effective exclusivity is not determined solely by a single compound patent. Fluorine-18 radiopharmaceuticals must be manufactured, released, transported, and administered within a narrow time window. That creates operational barriers even when legal patent protection is limited.
What is the Orange Book status of Tauvid?
Tauvid is listed in FDA drug databases as an approved NDA product. Its Orange Book position should be assessed separately from patent ownership because not every diagnostic radiopharmaceutical patent is necessarily listed in the same manner as patents for conventional prescription drugs.[3]
There is no established public record of a major Tauvid Paragraph IV litigation campaign comparable to those involving high-revenue chronic therapies. No widely reported generic launch date has been established.
When does Tauvid lose exclusivity?
Tauvid’s FDA approval date was May 28, 2020. Standard new-chemical-entity exclusivity, if applicable to the approved active moiety, would ordinarily have ended in 2025. Diagnostic radiopharmaceutical exclusivity may also be affected by the applicable FDA product classification and the nature of the active ingredient.
Patent expiry dates cannot be reliably reduced to one date without identifying each enforceable patent, terminal disclaimer, patent-term adjustment, jurisdiction, and licensing chain. In commercial terms, Tauvid’s competitive exposure is likely to increase as regulatory exclusivity and key patent rights expire, but practical entry remains constrained by production and distribution requirements.
Are there Paragraph IV challenges or Tauvid litigation?
No major, widely reported Paragraph IV challenge or high-value patent settlement involving Tauvid has established a public generic-entry timetable.
Potential disputes could involve:
- Flortaucipir composition claims.
- Radiolabeling processes.
- PET imaging methods.
- Manufacturing specifications.
- Use of Tauvid in Alzheimer’s disease staging.
- Distribution and supply agreements.
- Regulatory approval of competing tau tracers.
What settlement agreements affect Tauvid?
No broadly disclosed settlement agreement has created a known authorized generic or fixed market-entry date for a competing flortaucipir product. The absence of a public settlement does not eliminate future challenge risk, particularly if the market expands through treatment selection and clinical-trial use.
How strong is the Tauvid patent estate?
Tauvid’s patent strength is best characterized as moderate when legal protection and operational barriers are evaluated together.
| Protection layer |
Relative strength |
Reason |
| Regulatory approval |
Moderate |
Supports commercial use but does not block all competing tracers |
| Compound rights |
Potentially significant |
Depends on surviving claims and expiration dates |
| Formulation rights |
Moderate |
Radiopharmaceutical formulation and stability can be difficult to replicate |
| Manufacturing know-how |
Strong operationally |
Requires validated radiochemistry and quality systems |
| Method-of-use rights |
Variable |
Broad diagnostic claims may face validity and freedom-to-operate issues |
| Distribution network |
Strong in established regions |
Short isotope half-life favors local infrastructure |
| Reader training and clinical adoption |
Moderate |
Creates switching costs but not legal exclusivity |
The strongest barrier is likely the integrated production and clinical workflow rather than any individual patent claim.
What market size and revenue exposure does Tauvid have?
Eli Lilly does not separately disclose Tauvid revenue in its principal public financial reporting. Tauvid is therefore a small product line relative to Lilly’s therapeutic portfolio, and company-wide revenue cannot be used as a direct measure of Tauvid sales.[4]
The addressable market includes:
- Memory clinics.
- Academic hospitals.
- PET imaging centers.
- Alzheimer’s disease clinical-trial sites.
- Specialist neurology practices with referral access.
- Research networks studying tau pathology.
- Health systems evaluating patients for disease-modifying therapy.
Commercial adoption is limited by the number of PET scanners, radiopharmacy sites, reimbursement policies, referral patterns, and the availability of trained image readers.
Tauvid market drivers
The main growth drivers are:
- Greater use of biomarker-confirmed Alzheimer’s diagnosis.
- Expansion of anti-amyloid treatment pathways.
- More clinical trials requiring disease-stage characterization.
- Increased demand for longitudinal tau imaging.
- Wider coverage by hospital-based PET programs.
- Physician familiarity with tau pathology.
Tauvid market constraints
The main constraints are:
- High cost of PET imaging.
- Limited reimbursement in some markets.
- Short product shelf life.
- Dependence on regional cyclotron and radiopharmacy capacity.
- Competition from blood-based biomarkers.
- Use of amyloid biomarkers as the more common treatment-eligibility test.
- Research preference for newer tau tracers.
What is the Tauvid market forecast through 2030?
A precise public consensus forecast for Tauvid sales is not available because Lilly does not report product-level revenue and market-research estimates vary by geography and reimbursement assumptions. A scenario-based projection is more appropriate.
| Scenario |
2025-2030 demand pattern |
Principal assumptions |
| Downside |
Flat to low single-digit annual growth |
Blood biomarkers displace PET; limited reimbursement; competing tracers gain trial share |
| Base case |
Mid-single-digit annual growth |
Stable specialist use, moderate anti-amyloid pathway expansion, continued research demand |
| Upside |
High-single-digit to low-double-digit annual growth |
Tau PET becomes more common in staging, treatment monitoring, and trial enrollment |
The base case is more likely to produce gradual market expansion than rapid blockbuster growth. Tauvid is a specialized diagnostic with a narrow workflow, and its commercial ceiling is determined by imaging capacity rather than the number of people with Alzheimer’s disease.
The largest upside would come from regulatory or clinical adoption of tau PET as a routine tool for treatment selection or disease monitoring. The largest downside would come from accurate blood-based tau biomarkers that provide lower-cost, scalable alternatives. Blood tests are unlikely to eliminate PET immediately because PET provides spatial information, but they can reduce the number of patients referred for expensive imaging.
What generic launch risks exist for Tauvid?
Generic or follow-on flortaucipir entry is possible but operationally complex.
Legal and regulatory risks
A competitor would need to address:
- NDA or ANDA pathway selection.
- Patent and exclusivity status.
- Bioequivalence or comparable imaging performance.
- Radiochemical purity.
- Sterility and endotoxin controls.
- Stability and expiration dating.
- PET image interpretation consistency.
- Manufacturing-site qualification.
- Distribution within the fluorine-18 half-life window.
A follow-on product could compete without being chemically identical in every commercial respect if it obtained approval for a comparable imaging indication through an appropriate FDA pathway. Competing tau tracers are a larger strategic threat than a conventional generic because they can target the same clinical decision with a different molecule.
Generic launch scenarios
| Launch scenario |
Likely market effect |
| Authorized generic flortaucipir |
Price pressure and faster hospital adoption |
| Independent flortaucipir entrant |
Regional competition where radiopharmacy capacity exists |
| New FDA-approved tau tracer |
Substitution risk, especially in clinical trials |
| Blood-based biomarker adoption |
Reduced PET referral volume |
| Expanded Tauvid reimbursement |
Higher utilization and stronger commercial retention |
How does Tauvid compare with amyloid PET agents?
Tauvid and amyloid PET agents answer different clinical questions.
| Attribute |
Tauvid |
Amyloid PET |
| Target |
Aggregated tau neurofibrillary tangles |
Amyloid plaques |
| Main use |
Estimate tau distribution and disease stage |
Detect amyloid pathology |
| Role in anti-amyloid therapy |
Potential staging and monitoring tool |
More directly relevant to amyloid confirmation |
| Regulatory maturity |
FDA-approved |
Multiple FDA-approved agents |
| Main limitation |
Interpretation and off-target binding |
Positive amyloid status does not establish symptomatic disease |
| Commercial use |
Specialist and research-heavy |
Broader eligibility and diagnostic use |
Tauvid is more exposed to competition from new tau tracers and blood-based tau tests than from amyloid PET products, although both categories compete for PET capacity and diagnostic budgets.
Key Takeaways
- Tauvid is flortaucipir F 18, an FDA-approved tau PET diagnostic marketed by Avid Radiopharmaceuticals and Eli Lilly.
- FDA approval occurred on May 28, 2020, under NDA 212123.
- Tauvid estimates aggregated tau neurofibrillary tangles but does not treat or independently diagnose Alzheimer’s disease.
- Clinical research is focused on disease staging, longitudinal progression, clinical-trial enrichment, and treatment-pathway support.
- No major public Paragraph IV challenge, generic launch date, or settlement has established a defined Tauvid entry event.
- The product’s commercial protection depends on patents, regulatory status, radiochemistry know-how, PET infrastructure, reader training, and distribution.
- Lilly does not separately disclose Tauvid revenue.
- The base-case market outlook is gradual growth through 2030, with upside from wider treatment-pathway use and downside from blood-based biomarkers and competing tau tracers.
- The largest competitive risk is a newer tau PET agent or scalable blood test, not a conventional generic alone.
FAQs
Is Tauvid a treatment for Alzheimer’s disease?
No. Tauvid is a diagnostic PET imaging agent used to estimate the distribution and density of aggregated tau pathology.
Can Tauvid determine whether a patient qualifies for lecanemab or donanemab?
Tauvid is not the primary approved eligibility test for anti-amyloid therapy. Treatment pathways generally require confirmation of amyloid pathology and assessment of clinical and safety criteria.
Does Tauvid detect amyloid plaques?
No. Tauvid targets aggregated tau. Amyloid PET agents target amyloid plaques.
Can Tauvid be used to monitor treatment response?
Tauvid may be used in research to study longitudinal tau changes, but the FDA-approved label does not establish Tauvid as a routine treatment-response monitoring test.
What is the main commercial threat to Tauvid?
The main threats are blood-based Alzheimer’s biomarkers, newer tau PET tracers selected for clinical trials, limited PET reimbursement, and the scarcity of radiopharmacy infrastructure.
References
- U.S. Food and Drug Administration. (2020). Tauvid (flortaucipir F 18 injection) prescribing information.
- National Library of Medicine. (n.d.). ClinicalTrials.gov: Studies using flortaucipir F 18.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- Eli Lilly and Company. (2024). Annual report and Form 10-K.
